Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 10, 2026Personalized Medicine

Digital biomarkers in chronic disease management: a systematic review of personalization and ethical challenges

View Full Paper
Ask AI
Bookmark
Share

Authors

SMShrivats ManikandanA.T. Still UniversitySSSteiv ShoreA.T. Still UniversityDWDaniel WaszczukA.T. Still University

Discussion

Loading...

Member takes

Overview

Systematic review evaluates digital biomarkers' efficacy and ethical hurdles in chronic disease management, emphasizing personalization and equity challenges.

Key Points

  • This review aims to evaluate the clinical performance of digital biomarkers and identify ethical challenges in chronic disease management.
  • Systematic review conducted following PRISMA guidelines.
  • Studies in English from PubMed (2010-2024) were evaluated, focusing on digital biomarkers in chronic disease management.
  • Quality assessment of studies was performed qualitatively due to the heterogeneity of designs and outcomes.
  • 68 studies included, covering various chronic diseases such as cardiovascular disease, diabetes, and respiratory conditions.
  • KardiaMobile showed 100% atrial fibrillation detection sensitivity; Embrace Watch demonstrated 92-94% seizure detection sensitivity.
  • Improved HbA1c with smart insulin pens (p=0.006) and better CPAP adherence (87% vs 74%) with smart monitoring were noted.

Cite This Study

Manikandan et al. (2026) studied this question.

synapsesocial.com/papers/6a28ff956f82f25be989c6dfhttps://doi.org/10.1080/17410541.2026.2682847
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Digital biomarkers in non-communicable diseases2026
  2. 2Challenges and potential of using digital biomarkers in healthcare and clinical trials2026
  3. 3Digital biomarkers in cardiovascular medicine: a scientific statement of the ESC Working Group on e-Cardiology, the ESC Working Group on Cardiovascular Pharmacotherapy, the European Heart Rhythm Association (EHRA) of the ESC, the Association for Acute Cardiovascular Care (ACVC) of the ESC, the Heart Failure Association (HFA) of the ESC, the European Association of Preventive Cardiology (EAPC) of the ESC, the European Association of Cardiovascular Imaging (EACVI) of the ESC, in collaboration with the Digital Cardiology and Artificial Intelligence Committee of the ESC, and the ESC Regulatory Affairs Committee2026
  4. 4Digital biomarkers: 3PM approach revolutionizing chronic disease management — EPMA 2024 position2024 · 69 citations
  5. 5Digital Resilience Biomarkers for Personalized Health Maintenance and Disease Prevention2021 · 31 citations